ChemoCentryx
Develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Launch date
Employees
Market cap
$3.7b
Enterprise valuation
$3.5b (Public information from Nov 2022)
Share price
$51.99 CCXI
San Carlos California (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 82.0m | 42.0m | 36.0m | 64.0m | 49.0m | 90.0m |
| % growth | - | - | (49 %) | (14 %) | 78 % | (23 %) | 84 % |
| EBITDA | - | 16.0m | (40.0m) | (53.0m) | (80.0m) | - | - |
| % EBITDA margin | - | 20 % | (95 %) | (147 %) | (125 %) | - | - |
| Profit | - | 17.0m | (38.0m) | (55.0m) | (55.0m) | (126m) | (144m) |
| % profit margin | - | 21 % | (90 %) | (153 %) | (86 %) | (257 %) | (160 %) |
| EV / revenue | - | 3.5x | 9.4x | 59.8x | 60.5x | 35.5x | 20.7x |
| EV / EBITDA | - | 18.1x | -9.8x | -40.6x | -48.4x | - | - |
| R&D budget | 27.5m | - | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $14.0m | Grant | |
$33.0m | Series B | ||
$17.7m | Series C | ||
$29.8m | Series D | ||
$50.0m | Series E | ||
| N/A | $45.0m | IPO | |
| N/A | $64.4m | Post IPO Equity | |
* | $100m | Post IPO Debt | |
* | N/A | $325m | Post IPO Equity |
* | $3.7b Valuation: $3.7b 75.5x EV/LTM Revenues | Acquisition | |
| Total Funding | $145m | ||
Related Content
Recent News about ChemoCentryx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.